Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Biodexa Pharmaceuticals

    MCap

    USD6m

    Last close

    USD1.30

    ▲ 0.58 (79.31%)

    Pharnext

    MCap

    1m

    Last close

    EUR0.10

    ▲ 0.03 (42.86%)

    MGI – Media and Games Invest

    MCap

    EUR235m

    Last close

    EUR1.50

    ▲ 0.35 (30.21%)

  • Sectors

    Sectors

  • Investment Strategy

    Investment Strategy

    View All

    Latest

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

AFT Pharmaceuticals (ASX: AFT)

Last close As at 26/04/2024

NZD3.09

▲ 0.02 (0.65%)

Market capitalisation

NZD325m

AFT Pharmaceuticals is a specialty pharmaceutical company that operates primarily in Australasia but has product distribution agreements across the globe. The company’s product portfolio includes prescription and over-the-counter (OTC) drugs to treat a range of conditions and a proprietary nebuliser.

AFT Pharmaceuticals is a multi-product company targeting pharmacy prescription, OTC and hospital markets. Data for Maxigesic offer it a competitive advantage in a fragmented industry.

Latest Insights

View More

Healthcare | Flash note

AFT Pharmaceuticals — Expanded R&D pipeline to fuel LT growth

Healthcare | Flash note

AFT Pharmaceuticals — Poised for international market expansion

Healthcare | Update

AFT Pharmaceuticals — US milestone triggers upside and guidance bump

Healthcare | Flash note

AFT Pharmaceuticals — US maiden voyage with Maxigesic IV launch
AFT-Pharmaceuticals_resized
Visit Website

Sector

Healthcare

Equity Analyst

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Nidhi Singh

Nidhi Singh

Analyst

Jyoti Prakash

Jyoti Prakash

Analyst, Healthcare

Arron Aatkar

Associate analyst

Key Management

  • David Flacks

    Chairman

  • Dr Hartley Atkinson

    CEO

  • Malcolm Tubby

    Chief Financial Officer

  • Michael Weinmann

    Member of the Board of Directors

  • Nathan D. Hukill

    Member of the Board of Directors

Balance Sheet

Forecast net debt (NZ$m)

25.6

Forecast gearing ratio (%)

29

Share Price Performance

Price Performance
% 1M 3M 12M
Actual 1.3 (15.8) (10.4)
Relative 3.3 (14.4) (6.5)
52 week high/low 3.9/2.8

Financials

While AFT continues to gain commercial traction from Maxigesic/ Combogesic IV sales in the US (launched by partner Hikma in Q1 CY24) and anticipates the launch of Crystaderm in China, a strong R&D pipeline is central to AFT’s long-term growth ambitions. AFT recently announced the seventh addition to its R&D portfolio, a non-invasive topical alternative treatment for keloid and hypertrophic scarring, addressing the limited treatment algorithm for keloid scars (raised, thickened scars). This development collaboration is with Massey Ventures and the Gillies McIndoe Research Institute, and continues AFT’s initial collaboration with these parties from 2022, for the treatment of strawberry birthmarks.

Y/E Mar Revenue (NZ$m) EBITDA (NZ$m) PBT (NZ$m) EPS (c) P/E (x) P/CF (x)
2022A 130.3 21.4 18.9 19.2 16.1 16.3
2023A 156.6 21.4 16.7 11.0 28.1 30.4
2024E 187.5 25.6 22.3 15.5 19.9 20.9
2025E 223.5 30.0 26.3 18.2 17.0 17.7

Research

Flash note

Healthcare

AFT Pharmaceuticals — Poised for international market expansion

Update

Healthcare

AFT Pharmaceuticals — US milestone triggers upside and guidance bump

Healthcare

Flash note

AFT Pharmaceuticals — Expanded R&D pipeline to fuel LT growth
View All

Thematics

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free